Autocrine VEGF-VEGFR2-Neuropilin-1 signaling promotes glioma stem-like cell viability and tumor growth

Journal of Experimental Medicine

Volumn 209, Issue 3, 2012, Pages 507-520

  Hamerlik, Petra ^a,b   Lathia, Justin D ^c   Rasmussen, Rikke ^a   Wu, Qiulian ^c   Bartkova, Jirina ^a   Lee, MyungHee ^a   Moudry, Pavel ^d   Bartek, Jiri ^a,b,d,e,f   Fischer, Walter ^e   Lukas, Jiri ^a   Rich, Jeremy N ^c  

^a DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

^b PALACKÝ UNIVERSITY   (Czech Republic)

^c LERNER RESEARCH INSTITUTE   (United States)

^d INSTITUTE OF MOLECULAR GENETICS   (Czech Republic)

^e University of Copenhagen   (Denmark)

^f KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CD133 ANTIGEN; NEUROPILIN 1; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2;

ARTICLE; AUTOCRINE EFFECT; CANCER STEM CELL; CELL VIABILITY; ENZYME ACTIVITY; GLIOMA; GLIOMA STEM LIKE CELL; HUMAN; PRIORITY JOURNAL; PROTEIN SECRETION; SIGNAL TRANSDUCTION; TUMOR GROWTH; TUMOR MICROENVIRONMENT;

ANTIBODIES, MONOCLONAL, HUMANIZED; AUTOCRINE COMMUNICATION; CELL PROLIFERATION; CELL SURVIVAL; ENDOSOMES; GLIOBLASTOMA; HUMANS; NEOPLASTIC STEM CELLS; NEOVASCULARIZATION, PATHOLOGIC; NEUROPILIN-1; RNA, SMALL INTERFERING; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 84860356630     PISSN: 00221007     EISSN: 15409538     Source Type: Journal    
DOI: 10.1084/jem.20111424     Document Type: Article

References (75)

1. Ballmer-Hofer, K., A.E. Andersson, L.E. Ratcliffe, and P. Berger. 2011. Neuropilin-1 promotes VEGFR-2 trafficking through Rab11 vesicles thereby specifying signal output. Blood. 118:816-826. http://dx.doi.org/10.1182/blood-2011-01-328773
2. Bao, S., Q. Wu, R.E. McLendon, Y. Hao, Q. Shi, A.B. Hjelmeland, M.W. Dewhirst, D.D. Bigner, and J.N. Rich. 2006a. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature. 444:756-760. http://dx.doi.org/10.1038/nature05236
3. Bao, S., Q. Wu, S. Sathornsumetee, Y. Hao, Z. Li, A.B. Hjelmeland, Q. Shi, R.E. McLendon, D.D. Bigner, and J.N. Rich. 2006b. Stem celllike glioma cells promote tumor angiogenesis through vascular endothelial growth factor. Cancer Res. 66:7843-7848. http://dx.doi.org/10.1158/0008-5472.CAN-06-1010
4. Bartkova, J., Z. Horejsí, K. Koed, A. Krämer, F. Tort, K. Zieger, P. Guldberg, M. Sehested, J.M. Nesland, C. Lukas, T. Ørntoft, J. Lukas, and J. Bartek. 2005. DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature. 434:864-870. httpx://dx.doi.org/10.1038/nature03482
5. Beier, D., P. Hau, M. Proescholdt, A. Lohmeier, J. Wischhusen, P.J. Oefner, L. Aigner, A. Brawanski, U. Bogdahn, and C.P. Beier. 2007. CD133(+) and CD133(-) glioblastoma-derived cancer stem cells show differential growth characteristics and molecular profiles. Cancer Res. 67:4010-4015. http://dx.doi.org/10.1158/0008-5472.CAN-06-4180
6. Butler, J.M., H. Kobayashi, and S. Rafii. 2010. Instructive role of the vascular niche in promoting tumour growth and tissue repair by angiocrine factors. Nat. Rev. Cancer. 10:138-146. http://dx.doi.org/10.1038/nrc2791
7. Calabrese, C., H. Poppleton, M. Kocak, T.L. Hogg, C. Fuller, B. Hamner, E.Y. Oh, M.W. Gaber, D. Finklestein, M. Allen, et al. 2007. A perivascular niche for brain tumor stem cells. Cancer Cell. 11:69-82. http://dx.doi.org/10.1016/j.ccr.2006.11.020
8. Christensen, K., H.D. Schrøder, and B.W. Kristensen. 2011. CD133+ niches and single cells in glioblastoma have different phenotypes. J. Neurooncol. 104:129-143. http://dx.doi.org/10.1007/s11060-010-0488-y
9. Citrin, D., C. Ménard, and K. Camphausen. 2006. Combining radiotherapy and angiogenesis inhibitors: clinical trial design. Int. J. Radiat. Oncol. Biol. Phys. 64:15-25. http://dx.doi.org/10.1016/j.ijrobp.2005.03.065
10. Desjardins, A., D.A. Reardon, J.E. Herndon II, J. Marcello, J.A. Quinn, J.N. Rich, S. Sathornsumetee, S. Gururangan, J. Sampson, L. Bailey, et al. 2008. Bevacizumab plus irinotecan in recurrent WHO grade 3 malignant gliomas. Clin. Cancer Res. 14:7068-7073. http://dx.doi.org/10.1158/1078-0432.CCR-08-0260
11. Ellis, L.M., and D.J. Hicklin. 2008. VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat. Rev. Cancer. 8:579-591. http://dx.doi.org/10.1038/nrc2403
12. Eyler, C.E., and J.N. Rich. 2008. Survival of the fittest: cancer stem cells in therapeutic resistance and angiogenesis. J. Clin. Oncol. 26:2839-2845. http://dx.doi.org/10.1200/JCO.2007.15.1829
13. Eyler, C.E., W.C. Foo, K.M. LaFiura, R.E. McLendon, A.B. Hjelmeland, and J.N. Rich. 2008. Brain cancer stem cells display preferential sensitivity to Akt inhibition. Stem Cells. 26:3027-3036. http://dx.doi.org/10.1634/stemcells.2007-1073
14. Ferrara, N., H.P. Gerber, and J. LeCouter. 2003. The biology of VEGF and its receptors. Nat. Med. 9:669-676. http://dx.doi.org/10.1038/nm0603-669
15. Folkins, C., S. Man, P. Xu, Y. Shaked, D.J. Hicklin, and R.S. Kerbel. 2007. Anticancer therapies combining antiangiogenic and tumor cell cytotoxic effects reduce the tumor stem-like cell fraction in glioma xenograft tumors. Cancer Res. 67:3560-3564. http://dx.doi.org/10.1158/0008-5472.CAN-06-4238
16. Folkins, C., Y. Shaked, S. Man, T. Tang, C.R. Lee, Z. Zhu, R.M. Hoffman, and R.S. Kerbel. 2009. Glioma tumor stem-like cells promote tumor angiogenesis and vasculogenesis via vascular endothelial growth factor and stromal-derived factor 1. Cancer Res. 69:7243-7251. http://dx.doi.org/10.1158/0008-5472.CAN-09-0167
17. Friedman, H.S., M.D. Prados, P.Y. Wen, T. Mikkelsen, D. Schiff, L.E. Abrey, W.K. Yung, N. Paleologos, M.K. Nicholas, R. Jensen, et al. 2009. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J. Clin. Oncol. 27:4733-4740. http://dx.doi.org/10.1200/JCO.2008.19.8721
18. Gampel, A., L. Moss, M.C. Jones, V. Brunton, J.C. Norman, and H. Mellor. 2006. VEGF regulates the mobilization of VEGFR2/KDR from an intracellular endothelial storage compartment. Blood. 108:2624-2631. http://dx.doi.org/10.1182/blood-2005-12-007484
19. Gilbertson, R.J., and J.N. Rich. 2007. Making a tumour's bed: glioblastoma stem cells and the vascular niche. Nat. Rev. Cancer. 7:733-736. http://dx.doi.org/10.1038/nrc2246
20. Gorski, D.H., M.A. Beckett, N.T. Jaskowiak, D.P. Calvin, H.J. Mauceri, R.M. Salloum, S. Seetharam, A. Koons, D.M. Hari, D.W. Kufe, and R.R. Weichselbaum. 1999. Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation. Cancer Res. 59:3374-3378.
21. Graeven, U., W. Fiedler, S. Karpinski, S. Ergün, N. Kilic, U. Rodeck, W. Schmiegel, and D.K. Hossfeld. 1999. Melanoma-associated expression of vascular endothelial growth factor and its receptors FLT-1 and KDR. J. Cancer Res. Clin. Oncol. 125:621-629. http://dx.doi.org/10.1007/s004320050325
22. Gururangan, S., S.N. Chi, T. Young Poussaint, A. Onar-Thomas, R.J. Gilbertson, S. Vajapeyam, H.S. Friedman, R.J. Packer, B.N. Rood, J.M. Boyett, and L.E. Kun. 2010. Lack of efficacy of bevacizumab plus irinotecan in children with recurrent malignant glioma and diffuse brainstem glioma: a Pediatric Brain Tumor Consortium study. J. Clin. Oncol. 28:3069-3075. http://dx.doi.org/10.1200/JCO.2009.26.8789
23. Hemmati, H.D., I. Nakano, J.A. Lazareff, M. Masterman-Smith, D.H. Geschwind, M. Bronner-Fraser, and H.I. Kornblum. 2003. Cancerous stem cells can arise from pediatric brain tumors. Proc. Natl. Acad. Sci. USA. 100:15178-15183. http://dx.doi.org/10.1073/pnas.2036535100
24. Hess, C., V. Vuong, I. Hegyi, O. Riesterer, J. Wood, D. Fabbro, C. Glanzmann, S. Bodis, and M. Pruschy. 2001. Effect of VEGF receptor inhibitor PTK787/ZK222584 [correction of ZK222548] combined with ionizing radiation on endothelial cells and tumour growth. Br. J. Cancer. 85:2010-2016. http://dx.doi.org/10.1054/bjoc.2001.2166
25. Hlobilkova, A., J. Ehrmann, P. Knizetova, V. Krejci, O. Kalita, and Z. Kolar. 2009. Analysis of VEGF, Flt-1, Flk-1, nestin and MMP-9 in relation to astrocytoma pathogenesis and progression. Neoplasma. 56:284-290. http://dx.doi.org/10.4149/neo_2009_04_284
26. Hu, B., P. Guo, I. Bar-Joseph, Y. Imanishi, M.J. Jarzynka, O. Bogler, T. Mikkelsen, T. Hirose, R. Nishikawa, and S.Y. Cheng. 2007. Neuropilin-1 promotes human glioma progression through potentiating the activity of the HGF/SF autocrine pathway. Oncogene. 26:5577-5586. http://dx.doi.org/10.1038/sj.onc.1210348
27. Ishida, S., K. Shinoda, S. Kawashima, Y. Oguchi, Y. Okada, and E. Ikeda. 2000. Coexpression of VEGF receptors VEGF-R2 and neuropilin-1 in proliferative diabetic retinopathy. Invest. Ophthalmol. Vis. Sci. 41: 1649-1656.
28. Iwamoto, F.M., and H.A. Fine. 2010. Bevacizumab for malignant gliomas. Arch. Neurol. 67:285-288. http://dx.doi.org/10.1001/archneurol.2010.11
29. Iwamoto, F.M., L.E. Abrey, K. Beal, P.H. Gutin, M.K. Rosenblum, V.E. Reuter, L.M. DeAngelis, and A.B. Lassman. 2009. Patterns of relapse and prognosis after bevacizumab failure in recurrent glioblastoma. Neurology. 73:1200-1206. http://dx.doi.org/10.1212/WNL.0b013e3181bc0184
30. Jarvis, A., C.K. Allerston, H. Jia, B. Herzog, A. Garza-Garcia, N. Winfield, K. Ellard, R. Aqil, R. Lynch, C. Chapman, et al. 2010. Small molecule inhibitors of the neuropilin-1 vascular endothelial growth factor A (VEGF-A) interaction. J. Med. Chem. 53:2215-2226. http://dx.doi.org/10.1021/jm901755g
31. Joo, K.M., S.Y. Kim, X. Jin, S.Y. Song, D.S. Kong, J.I. Lee, J.W. Jeon, M.H. Kim, B.G. Kang, Y. Jung, et al. 2008. Clinical and biological implications of CD133-positive and CD133-negative cells in glioblastomas. Lab. Invest. 88:808-815. http://dx.doi.org/10.1038/labinvest.2008.57
32. Jopling, H.M., G.J. Howell, N. Gamper, and S. Ponnambalam. 2011. The VEGFR2 receptor tyrosine kinase undergoes constitutive endosome-to-plasma membrane recycling. Biochem. Biophys. Res. Commun. 410:170-176. http://dx.doi.org/10.1016/j.bbrc.2011.04.093
33. Knizetova, P., J. Ehrmann, A. Hlobilkova, I. Vancova, O. Kalita, Z. Kolar, and J. Bartek. 2008. Autocrine regulation of glioblastoma cell cycle progression, viability and radioresistance through the VEGF-VEGFR2 (KDR) interplay. Cell Cycle. 7:2553-2561. http://dx.doi.org/10.4161/cc.7.16.6442
34. Kremer, C., G. Breier, W. Risau, and K.H. Plate. 1997. Up-regulation of flk-1/vascular endothelial growth factor receptor 2 by its ligand in a cerebral slice culture system. Cancer Res. 57:3852-3859.
35. Lai, A., A. Tran, P.L. Nghiemphu, W.B. Pope, O.E. Solis, M. Selch, E. Filka, W.H. Yong, P.S. Mischel, L.M. Liau, et al. 2011. Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme. J. Clin. Oncol. 29:142-148. http://dx.doi.org/10.1200/JCO.2010.30.2729
36. Lampugnani, M.G., F. Orsenigo, M.C. Gagliani, C. Tacchetti, and E. Dejana. 2006. Vascular endothelial cadherin controls VEGFR-2 internalization and signaling from intracellular compartments. J. Cell Biol. 174:593-604. http://dx.doi.org/10.1083/jcb.200602080
37. Lathia, J.D., J. Gallagher, J.M. Heddleston, J. Wang, C.E. Eyler, J. Macswords, Q. Wu, A. Vasanji, R.E. McLendon, A.B. Hjelmeland, and J.N. Rich. 2010. Integrin alpha 6 regulates glioblastoma stem cells. Cell Stem Cell. 6:421-432. http://dx.doi.org/10.1016/j.stem.2010.02.018
38. Leone, D.P., J.B. Relvas, L.S. Campos, S. Hemmi, C. Brakebusch, R. Fässler, C. Ffrench-Constant, and U. Suter. 2005. Regulation of neural progenitor proliferation and survival by beta1 integrins. J. Cell Sci. 118:2589-2599. http://dx.doi.org/10.1242/jcs.02396
39. Li, Z., S. Bao, Q. Wu, H. Wang, C. Eyler, S. Sathornsumetee, Q. Shi, Y. Cao, J. Lathia, R.E. McLendon, et al. 2009a. Hypoxia-inducible factors regulate tumorigenic capacity of glioma stem cells. Cancer Cell. 15:501-513. http://dx.doi.org/10.1016/j.ccr.2009.03.018
40. Li, Z., H. Wang, C.E. Eyler, A.B. Hjelmeland, and J.N. Rich. 2009b. Turning cancer stem cells inside out: an exploration of glioma stem cell signaling pathways. J. Biol. Chem. 284:16705-16709. http://dx.doi.org/10.1074/jbc.R900013200
41. Liu, G., X. Yuan, Z. Zeng, P. Tunici, H. Ng, I.R. Abdulkadir, L. Lu, D. Irvin, K.L. Black, and J.S. Yu. 2006. Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma. Mol. Cancer. 5:67. http://dx.doi.org/10.1186/1476-4598-5-67
42. Mac Gabhann, F., and A.S. Popel. 2006. Targeting neuropilin-1 to inhibit VEGF signaling in cancer: Comparison of therapeutic approaches. PLOS Comput. Biol. 2:e180. http://dx.doi.org/10.1371/journal.pcbi.0020180
43. Meissner, M., G. Reichenbach, M. Stein, I. Hrgovic, R. Kaufmann, and J. Gille. 2009. Down-regulation of vascular endothelial growth factor receptor 2 is a major molecular determinant of proteasome inhibitor-mediated antiangiogenic action in endothelial cells. Cancer Res. 69:1976-1984. http://dx.doi.org/10.1158/0008-5472.CAN-08-3150
44. Moffat, J., D.A. Grueneberg, X. Yang, S.Y. Kim, A.M. Kloepfer, G. Hinkle, B. Piqani, T.M. Eisenhaure, B. Luo, J.K. Grenier, et al. 2006. A lentiviral RNAi library for human and mouse genes applied to an arrayed viral high-content screen. Cell. 124:1283-1298. http://dx.doi.org/10.1016/j.cell.2006.01.040
45. Newman, P.J., M.C. Berndt, J. Gorski, G.C. White II, S. Lyman, C. Paddock, and W.A. Muller. 1990. PECAM-1 (CD31) cloning and relation to adhesion molecules of the immunoglobulin gene superfamily. Science. 247:1219-1222. http://dx.doi.org/10.1126/science.1690453
46. Norden, A.D., and P.Y. Wen. 2006. Glioma therapy in adults. Neurologist. 12:279-292. http://dx.doi.org/10.1097/01.nrl.0000250928.26044.47
47. Norden, A.D., J. Drappatz, and P.Y. Wen. 2009. Antiangiogenic therapies for high-grade glioma. Nat. Rev. Neurol. 5:610-620. http://dx.doi.org/10.1038/nrneurol.2009.159
48. Ogden, A.T., A.E. Waziri, R.A. Lochhead, D. Fusco, K. Lopez, J.A. Ellis, J. Kang, M. Assanah, G.M. McKhann, M.B. Sisti, et al. 2008. Identification of A2B5+CD133- tumor-initiating cells in adult human gliomas. Neurosurgery. 62:505-514. http://dx.doi.org/10.1227/01.neu.0000316019.28421.95
49. Ostrowski, M., N.B. Carmo, S. Krumeich, I. Fanget, G. Raposo, A. Savina, C.F. Moita, K. Schauer, A.N. Hume, R.P. Freitas, et al. 2010. Rab27a and Rab27b control different steps of the exosome secretion pathway. Nat. Cell Biol. 12:19-30.
50. Pan, Q., Y. Chanthery, W.C. Liang, S. Stawicki, J. Mak, N. Rathore, R.K. Tong, J. Kowalski, S.F. Yee, G. Pacheco, et al. 2007. Blocking neuropilin-1 function has an additive effect with anti-VEGF to inhibit tumor growth. Cancer Cell. 11:53-67. http://dx.doi.org/10.1016/j.ccr.2006.10.018
51. Reya, T., S.J. Morrison, M.F. Clarke, and I.L. Weissman. 2001. Stem cells, cancer, and cancer stem cells. Nature. 414:105-111. http://dx.doi.org/10.1038/35102167
52. Ricci-Vitiani, L., R. Pallini, M. Biffoni, M. Todaro, G. Invernici, T. Cenci, G. Maira, E.A. Parati, G. Stassi, L.M. Larocca, and R. De Maria. 2010. Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells. Nature. 468:824-828. http://dx.doi.org/10.1038/nature09557
53. Rich, J.N. 2007. Cancer stem cells in radiation resistance. Cancer Res. 67:8980-8984. http://dx.doi.org/10.1158/0008-5472.CAN-07-0895
54. Roberts, M., S. Barry, A. Woods, P. van der Sluijs, and J. Norman. 2001. PDGF-regulated rab4-dependent recycling of alphavbeta3 integrin from early endosomes is necessary for cell adhesion and spreading. Curr. Biol. 11:1392-1402. http://dx.doi.org/10.1016/S0960-9822(01)00442-0
55. Rosenstein, J.M., and J.M. Krum. 2004. New roles for VEGF in nervous tissue-beyond blood vessels. Exp. Neurol. 187:246-253. http://dx.doi.org/10.1016/j.expneurol.2004.01.022
56. Sakariassen, P.O., L. Prestegarden, J. Wang, K.O. Skaftnesmo, R. Mahesparan, C. Molthoff, P. Sminia, E. Sundlisaeter, A. Misra, B.B. Tysnes, et al. 2006. Angiogenesis-independent tumor growth mediated by stem-like cancer cells. Proc. Natl. Acad. Sci. USA. 103:16466-16471. http://dx.doi.org/10.1073/pnas.0607668103
57. Shen, R., Y. Ye, L. Chen, Q. Yan, S.H. Barsky, and J.X. Gao. 2008. Precancerous stem cells can serve as tumor vasculogenic progenitors. PLoS ONE. 3:e1652. http://dx.doi.org/10.1371/journal.pone.0001652
58. Shibuya, M. 2008. Vascular endothelial growth factor-dependent and -independent regulation of angiogenesis. BMB Rep. 41:278-286. http://dx.doi.org/10.5483/BMBRep.2008.41.4.278
59. Shintani, S., C. Li, M. Mihara, S.K. Klosek, N. Terakado, S. Hino, and H. Hamakawa. 2006. Anti-tumor effect of radiation response by combined treatment with angiogenesis inhibitor, TNP-470, in oral squamous cell carcinoma. Oral Oncol. 42:66-72. http://dx.doi.org/10.1016/j.oraloncology.2005.06.010
60. Singh, S.K., I.D. Clarke, M. Terasaki, V.E. Bonn, C. Hawkins, J. Squire, and P.B. Dirks. 2003. Identification of a cancer stem cell in human brain tumors. Cancer Res. 63:5821-5828.
61. Soda, Y., T. Marumoto, D. Friedmann-Morvinski, M. Soda, F. Liu, H. Michiue, S. Pastorino, M. Yang, R.M. Hoffman, S. Kesari, and I.M. Verma. 2011. Transdifferentiation of glioblastoma cells into vascular endothelial cells. Proc. Natl. Acad. Sci. USA. 108:4274-4280. http://dx.doi.org/10.1073/pnas.1016030108
62. Soker, S., H.Q. Miao, M. Nomi, S. Takashima, and M. Klagsbrun. 2002. VEGF165 mediates formation of complexes containing VEGFR-2 and neuropilin-1 that enhance VEGF165-receptor binding. J. Cell. Biochem. 85:357-368. http://dx.doi.org/10.1002/jcb.10140
63. Son, M.J., K. Woolard, D.H. Nam, J. Lee, and H.A. Fine. 2009. SSEA-1 is an enrichment marker for tumor-initiating cells in human glioblastoma. Cell Stem Cell. 4:440-452. http://dx.doi.org/10.1016/j.stem.2009.03.003
64. Stewart, S.A., D.M. Dykxhoorn, D. Palliser, H. Mizuno, E.Y. Yu, D.S. An, D.M. Sabatini, I.S. Chen, W.C. Hahn, P.A. Sharp, et al. 2003. Lentivirus-delivered stable gene silencing by RNAi in primary cells. RNA. 9:493-501. http://dx.doi.org/10.1261/rna.2192803
65. Tiscornia, G., O. Singer, and I.M. Verma. 2006. Production and purification of lentiviral vectors. Nat. Protoc. 1:241-245. http://dx.doi.org/10.1038/nprot.2006.37
66. Tokuyama, W., T. Mikami, M. Masuzawa, and I. Okayasu. 2010. Autocrine and paracrine roles of VEGF/VEGFR-2 and VEGF-C/VEGFR-3 signaling in angiosarcomas of the scalp and face. Hum. Pathol. 41:407-414. http://dx.doi.org/10.1016/j.humpath.2009.08.021
67. Verhoeff, J.J., O. van Tellingen, A. Claes, L.J. Stalpers, M.E. van Linde, D.J. Richel, W.P. Leenders, and W.R. van Furth. 2009. Concerns about anti-angiogenic treatment in patients with glioblastoma multiforme. BMC Cancer. 9:444. http://dx.doi.org/10.1186/1471-2407-9-444
68. Verhoeff, J.J., C. Lavini, M.E. van Linde, L.J. Stalpers, C.B. Majoie, J.C. Reijneveld, W.R. van Furth, and D.J. Richel. 2010. Bevacizumab and dose-intense temozolomide in recurrent high-grade glioma. Ann. Oncol. 21:1723-1727. http://dx.doi.org/10.1093/annonc/mdp591
69. Vredenburgh, J.J., A. Desjardins, J.E. Herndon II, J. Marcello, D.A. Reardon, J.A. Quinn, J.N. Rich, S. Sathornsumetee, S. Gururangan, J. Sampson, et al. 2007. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J. Clin. Oncol. 25:4722-4729. http://dx.doi.org/10.1200/JCO.2007.12.2440
70. Wang, J., P.O. Sakariassen, O. Tsinkalovsky, H. Immervoll, S.O. Bøe, A. Svendsen, L. Prestegarden, G. Røsland, F. Thorsen, L. Stuhr, et al. 2008. CD133 negative glioma cells form tumors in nude rats and give rise to CD133 positive cells. Int. J. Cancer. 122:761-768. http://dx.doi.org/10.1002/ijc.23130
71. Wang, R., K. Chadalavada, J. Wilshire, U. Kowalik, K.E. Hovinga, A. Geber, B. Fligelman, M. Leversha, C. Brennan, and V. Tabar. 2010. Glioblastoma stem-like cells give rise to tumour endothelium. Nature. 468:829-833. http://dx.doi.org/10.1038/nature09624
72. Wherlock, M., A. Gampel, C. Futter, and H. Mellor. 2004. Farnesyltransferase inhibitors disrupt EGF receptor traffic through modulation of the RhoB GTPase. J. Cell Sci. 117:3221-3231. http://dx.doi.org/10.1242/jcs.01193
73. Winkler, F., S.V. Kozin, R.T. Tong, S.S. Chae, M.F. Booth, I. Garkavtsev, L. Xu, D.J. Hicklin, D. Fukumura, E. di Tomaso, et al. 2004. Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell. 6:553-563.
74. Wu, Y., and P.Y. Wu. 2009. CD133 as a marker for cancer stem cells: progresses and concerns. Stem Cells Dev. 18:1127-1134. http://dx.doi.org/10.1089/scd.2008.0338
75. Xiao, Z., Y. Kong, S. Yang, M. Li, J. Wen, and L. Li. 2007. Upregulation of Flk-1 by bFGF via the ERK pathway is essential for VEGF-mediated promotion of neural stem cell proliferation. Cell Res. 17:73-79. http://dx.doi.org/10.1038/sj.cr.7310126